
|Articles|March 15, 2003
Miravant to seek FDA approval for SnET2
Santa Barbara, CA-Miravant Medical Technologies will file its first new drug application for marketing approval of PhotoPoint SnET2, for the treatment of wet age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
AAO 2025: Kenneth C. Fan, MD, sees vision gains with MCO-010 in Stargardt disease
3
AAO 2025: Understanding and diagnosing endophthalmitis
4
AAO 2025: Diana Do reviews the real-world use of aflibercept 8 mg
5